Biotechnology stocks continued the blood shed on Monday. Shares across the sector tumbled several percentage points, along with exchange traded funds specializing in the industry. This constant downhill slide started last week and is raising questions among investors on whether the sector is finally running out of momentum, following news that U.S. lawmakers have asked Gilead Sciences Inc to explain the $84,000 price tag of its new hepatitis C drug.

If you liked this article you might like

These Stocks Pay You to Own Them

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition